Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes
- PMID: 15447734
- DOI: 10.1111/j.1742-7843.2004.950302.x
Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes
Abstract
This study aimed to investigate the effect of omeprazole on intragastric pH and gastrin release as well as the plasma concentration of omeprazole in relation to CYP2C19 genotypes after repeated doses in Korean patients. Twenty-six Korean patients with acid related disease were genotyped for CYP2C19 by allele specific PCR (wt/wt, CYP2C19*1/*1; wt/mut, CYP2C19*1/*2 or *1/*3; mut/mut, CYP2C19*2/*2, *2/*3 or *3/*3). Intragastric pH was monitored during 24 hr, and the plasma concentrations of omeprazole, hydroxyomeprazole, omeprazole sulfone and meal-stimulated gastrin were measured during 4 hr before and after 8 consecutive daily doses of 20 mg omeprazole. Unexpectedly the AUCs of omeprazole in the three genotypes were similarly high on Day 8. The mean 24 hr pH increased significantly in all three genotypes (paired t-test; P<0.0001), and the AUCs (4 hr) of gastrin in all patients increased markedly from 129+/-73 to 298+/-142 pMhr (P<0.0001). However, there was no statistically significant difference between the three genotypes in the mean pH and gastrin AUCs on Day 8. After 8 consecutive doses of 20 mg omeprazole, the gastric pH and the plasma gastrin were increased significantly in all three CYP2C19 genotypes, which were confirmed by high plasma concentrations of omeprazole in all three genotype groups. We suggest that the reason why the wt/wt had high concentrations of omeprazole similar to those in the other two genotype groups is that some of them were old with low CYP2C19 activity. In these patients omeprazole accumulated from the first to the eighth dose similar to that in the heterozygotes.
Similar articles
-
Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.Gastroenterology. 2000 Sep;119(3):670-6. doi: 10.1053/gast.2000.16515. Gastroenterology. 2000. PMID: 10982760
-
Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.World J Gastroenterol. 2006 Aug 7;12(29):4750-3. doi: 10.3748/wjg.v12.i29.4750. World J Gastroenterol. 2006. PMID: 16937451 Free PMC article. Clinical Trial.
-
Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.Aliment Pharmacol Ther. 2001 Dec;15(12):1929-37. doi: 10.1046/j.1365-2036.2001.01108.x. Aliment Pharmacol Ther. 2001. PMID: 11736724 Clinical Trial.
-
CYP2C19 genotype and the PPIs--focus on rabeprazole.J Gastroenterol Hepatol. 2005 Dec;20 Suppl:S22-8. doi: 10.1111/j.1440-1746.2005.04167.x. J Gastroenterol Hepatol. 2005. PMID: 16359346 Review.
-
Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.J Gastroenterol Hepatol. 2005 Dec;20 Suppl:S20-1. doi: 10.1111/j.1440-1746.2005.04179.x. J Gastroenterol Hepatol. 2005. PMID: 16359345 Review. No abstract available.
Cited by
-
Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.Eur J Clin Pharmacol. 2009 Jun;65(6):601-8. doi: 10.1007/s00228-008-0608-1. Epub 2009 Jan 27. Eur J Clin Pharmacol. 2009. PMID: 19172254 Clinical Trial.
-
Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.Dig Dis Sci. 2007 Feb;52(2):390-5. doi: 10.1007/s10620-006-9490-9. Epub 2007 Jan 9. Dig Dis Sci. 2007. PMID: 17211705 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases